Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 1.00 |
| ▸ | MMP2 | P08253 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 11/20 | 1.00 |
| ▸ | EGFR | P00533 | 8/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 0.77 |
| ▸ | MAOB | P27338 | 2/20 | 0.77 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | NMT1 | P30419 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | TOP2A | P11388 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-P-Tolylcinnamamide SCHEMBL1603280 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOA | |
| SCHEMBL11301842 | 0.95 | MMP1 (0.91) | MMP1MMP2MMP9EGFRMAOA | |
| SCHEMBL26120769 | 0.93 | MMP1 (0.88) | MMP1MMP2MMP9EGFRMAOA | |
| SCHEMBL13425358 | 0.91 | MMP1 (0.87) | MMP1MMP2MMP9EGFRMAOA | |
| SCHEMBL11590995 | 0.91 | EGFR (0.92) | MMP1MMP2MMP9EGFRMAOA | |
| SCHEMBL28269387 | 0.88 | MMP1 (0.78) | MMP1MMP2MMP9EGFRMAOA | |
| N-Phenylcinnamamide SCHEMBL3667414 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOA | |
| N-Phenylcinnamamide SCHEMBL4205896 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOA | |
| N-Phenylcinnamamide SCHEMBL2682029 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOA | |
| SCHEMBL3030602 | 0.86 | MMP1 (0.79) | MMP1MMP2MMP9EGFRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119998260-A | Process for preparing amides from esters | 巴斯夫欧洲公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| CN-111217694-B | Method for selectively reducing carbon-carbon double bond in alpha, beta-unsaturated carbonyl compound | 五邑大学 | 2022-09-30 | — | — | CN | disclosed |
| EP-3428162-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | Merial Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9663468-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| EP-1905762-A1 | PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-04-02 | — | — | EP | disclosed |
| EP-1900728-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007096618-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-5112837-A | Inhibitors of thymidylate synthetase enzyme | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | MMP1 1457/4885MMP2 1276/4885MMP9 953/4885 |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | MMP1 345/4885MMP2 3140/4885MMP9 2907/4885 |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | MMP1 1457/4885MMP2 1276/4885MMP9 953/4885 |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NOS2, NOS3, NOS1 | MMP1 4426/4885MMP2 2465/4885MMP9 3081/4885 |
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | RB1, RBBP5, RRM2B | MMP1 3817/4885MMP2 4170/4885MMP9 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.